- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02295358
The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface
8. juli 2015 opdateret af: University of Colorado, Denver
This study is designed with the intention to further elucidate the effects of omega-3 fatty acids on intraocular pressure (IOP) and signs/symptoms of dry eye.
Prior studies have shown statistically significant lowering of IOP with use of omega-3 fatty acids but have only been performed in animal models.
This study will be the first to attempt replication in human models.
A limited number of studies have shown an increase in tear production/volume as well as a decrease in the subjective symptoms of dry eye, but more studies are needed to better define these effects.
Better understanding of the effects of this supplement on intraocular pressure and dry eye will contribute to the expanding knowledge about the pathophysiology of glaucoma/ocular hypertension and dry eye syndrome and potentially lead to further studies about new potential treatment options for these conditions.
Studieoversigt
Status
Trukket tilbage
Betingelser
Detaljeret beskrivelse
The purpose of this research project is to determine the effects of omega-3 fatty acid supplementation on intraocular pressure (IOP) as well as the signs and symptoms of dry eye.
We hypothesize that dietary omega-3 fatty acid supplementation will be associated with a significant change in intraocular pressure compared to baseline measurements prior to beginning supplementation.
We further hypothesize that omega-3 fatty acid supplementation will be associated with a significant increase in tear production and volume as well as a significant change in patients' subjective complaints of dry eye.
Undersøgelsestype
Observationel
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- University of Colorado Eye Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
40 år til 89 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Diagnosis of Ocular Hypertension or Open Angle Glaucoma of mild to moderate severity, with or without previously diagnosed dry eye syndrome, who are currently on monotherapy with a prostaglandin analog.
Age 40-89 of either gender, of any race/ethnicity
Beskrivelse
Inclusion Criteria:
- Diagnosis of Ocular Hypertension or Open Angle Glaucoma of mild to moderate severity, with or without previously diagnosed dry eye syndrome, who are currently on monotherapy with a prostaglandin analog.
- Age 40-89 of either gender, of any race/ethnicity
Exclusion Criteria:
- Females who are currently pregnant or planning to become pregnant during the study period
- Age <40 years old
- Diagnosis of any other form of glaucoma other than open-angle
- Patients with known hypersensitivity (i.e., anaphylactic reaction) to omega-3 fatty acids or any of its components
- Patients with cirrhosis or with known liver disease
- Patients with diagnosed celiac disease
- Patients with a hypersensitivity to fish or shellfish
- Patients with paroxysmal or persistent atrial fibrillation
- Patients who are currently using medical or recreational marijuana
- Patients currently on any anticoagulation therapy including warfarin, dabigatran, apixaban, rivaroxaban, clopidogrel, cilostazol, dipyridamole, prasugrel, ticlopidine, ticagrelor
- Patients currently on Lovaza, an omega- 3 fatty acid supplement requiring a prescription
- Patients with any recent ocular surgery or laser treatment within 3 months
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure
Tidsramme: Change in intraocular pressure from baseline over 3 month
|
Intraocular pressure is measured at the study start, and after three month on supplementation.
|
Change in intraocular pressure from baseline over 3 month
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The Effect of Omega-3 Fatty Acid Supplementation on Ocular Surface
Tidsramme: Change in Ocular Surface from baseline over 3 month
|
Tear breakup time, corneal fluorescein staining, and tear osmolarity of Ocular Surface is measured at the study start, and after three month on supplementation
|
Change in Ocular Surface from baseline over 3 month
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Leonard K Seibold, MD, University of Colorado, Denver
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. november 2014
Primær færdiggørelse (Forventet)
1. november 2015
Studieafslutning (Forventet)
1. november 2015
Datoer for studieregistrering
Først indsendt
13. november 2014
Først indsendt, der opfyldte QC-kriterier
17. november 2014
Først opslået (Skøn)
20. november 2014
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
9. juli 2015
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
8. juli 2015
Sidst verificeret
1. juli 2015
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 14-0235
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Okulær hypertension
-
University of Central FloridaAfsluttet
-
Sherin Alaa Eldin Eisa ElsayedCairo UniversityUkendtOral sygdom | Muco-Cutaneo-Ocular Syndrome
-
University of Texas Southwestern Medical CenterAfsluttetSpace Flight Associated Neuro-ocular SyndromeForenede Stater
-
University of VirginiaNational Institute on Deafness and Other Communication Disorders (NIDCD)AfsluttetVestibulære funktionstest | mHealth ansøgning | Vestibulær funktionsforstyrrelse | Vestibulo-Ocular Reflex (VOR) DysfunktionForenede Stater
-
Selcuk UniversityAfsluttetNystagmus Vestibulær | Positionel Vertigo | Reflekser, Vestibo-OcularKalkun
-
VIVUS LLCIkke rekrutterer endnuPulmonal arteriel hypertension | Pulmonal arteriel hypertension (PAH) (WHO Group 1 PH) | Pulmonal arteriel hypertension (PAH) | Pulmonal arteriel hypertension WHO gruppe I | Pulmonal arteriel hypertension PAH
-
Inhibikase TherapeuticsIkke rekrutterer endnuPulmonal arteriel hypertension (PAH)
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyIkke rekrutterer endnu
-
BayerAfsluttet
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc...Ikke rekrutterer endnuPulmonal hypertension | Pulmonal arteriel hypertension (PAH)Forenede Stater